• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

三阴性乳腺癌的分类：见解与当前治疗方法

Classifications of triple-negative breast cancer: insights and current therapeutic approaches.

作者信息

Chen Ziqi, Liu Yumeng, Lyu Minchuan, Chan Chi Ho, Sun Meiheng, Yang Xin, Qiao Shuangying, Chen Zheng, Yu Sifan, Ren Meishen, Lu Aiping, Zhang Ge, Li Fangfei, Yu Yuanyuan

机构信息

Institute of Systems Medicine and Health Sciences, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, SAR, China.

Guangdong-Hong Kong-Macao Greater Bay Area International Research Platform for Aptamer-Based Translational Medicine and Drug Discovery, Hong Kong, SAR, China.

出版信息

Cell Biosci. 2025 Feb 1;15(1):13. doi: 10.1186/s13578-025-01359-0.

DOI:10.1186/s13578-025-01359-0
PMID:39893480
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11787746/
Abstract

Triple-negative breast cancer (TNBC) is an aggressive and challenging type of cancer, characterized by the absence of specific receptors targeted by current therapies, which limits effective targeted treatment options. TNBC has a high risk of recurrence and distant metastasis, resulting in lower survival rates. Additionally, TNBC exhibits significant heterogeneity at histopathological, proteomic, transcriptomic, and genomic levels, further complicating the development of effective treatments. While some TNBC subtypes may initially respond to chemotherapy, resistance frequently develops, increasing the risk of aggressive recurrence. Therefore, precisely classifying and characterizing the distinct features of TNBC subtypes is crucial for identifying the most suitable molecular-based therapies for individual patients. In this review, we provide a comprehensive overview of these subtypes, highlighting their unique profiles as defined by various classification systems. We also address the limitations of conventional therapeutic approaches and explore innovative biological strategies, all aimed at advancing the development of targeted and effective therapeutic strategies for TNBC.

摘要

三阴性乳腺癌（TNBC）是一种侵袭性且具有挑战性的癌症类型，其特征是缺乏当前疗法所针对的特定受体，这限制了有效的靶向治疗选择。TNBC具有高复发风险和远处转移风险，导致生存率较低。此外，TNBC在组织病理学、蛋白质组学、转录组学和基因组水平上表现出显著的异质性，这进一步使有效治疗的开发复杂化。虽然一些TNBC亚型最初可能对化疗有反应，但耐药性经常出现，增加了侵袭性复发的风险。因此，精确分类和表征TNBC亚型的独特特征对于为个体患者确定最合适的基于分子的疗法至关重要。在这篇综述中，我们全面概述了这些亚型，突出了它们由各种分类系统定义的独特特征。我们还讨论了传统治疗方法的局限性，并探索创新的生物学策略，所有这些都旨在推动TNBC靶向和有效治疗策略的发展。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8ae/11787746/34ee4f949659/13578_2025_1359_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8ae/11787746/110db81ce0d4/13578_2025_1359_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8ae/11787746/7401e4ffbbbc/13578_2025_1359_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8ae/11787746/a4f1819632ea/13578_2025_1359_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8ae/11787746/04e350a59b89/13578_2025_1359_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8ae/11787746/be5ef0e7f7c1/13578_2025_1359_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8ae/11787746/34ee4f949659/13578_2025_1359_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8ae/11787746/110db81ce0d4/13578_2025_1359_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8ae/11787746/7401e4ffbbbc/13578_2025_1359_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8ae/11787746/a4f1819632ea/13578_2025_1359_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8ae/11787746/04e350a59b89/13578_2025_1359_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8ae/11787746/be5ef0e7f7c1/13578_2025_1359_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8ae/11787746/34ee4f949659/13578_2025_1359_Fig6_HTML.jpg

相似文献

1
Classifications of triple-negative breast cancer: insights and current therapeutic approaches.三阴性乳腺癌的分类：见解与当前治疗方法
Cell Biosci. 2025 Feb 1;15(1):13. doi: 10.1186/s13578-025-01359-0.
2
Prognostic Significance and Molecular Classification of Triple Negative Breast Cancer: A Systematic Review.三阴性乳腺癌的预后意义与分子分类：一项系统评价
Eur J Breast Health. 2025 Mar 25;21(2):101-114. doi: 10.4274/ejbh.galenos.2025.2024-10-2. Epub 2025 Mar 3.
3
An update on cancer stem cell survival pathways involved in chemoresistance in triple-negative breast cancer.三阴性乳腺癌中与化疗耐药相关的癌症干细胞存活途径的最新进展。
Future Oncol. 2025 Mar;21(6):715-735. doi: 10.1080/14796694.2025.2461443. Epub 2025 Feb 12.
4
Current Triple-Negative Breast Cancer Subtypes: Dissecting the Most Aggressive Form of Breast Cancer.当前三阴性乳腺癌亚型：剖析最具侵袭性的乳腺癌形式。
Front Oncol. 2021 Jun 16;11:681476. doi: 10.3389/fonc.2021.681476. eCollection 2021.
5
Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy.三阴性乳腺癌的现行治疗策略：手术、放疗和化疗的适当结合。
Breast Cancer. 2011 Jul;18(3):165-73. doi: 10.1007/s12282-011-0254-9. Epub 2011 Feb 3.
6
Triple-negative breast cancer: A run-through of features, classification and current therapies.三阴性乳腺癌：特征、分类及当前治疗方法概述
Oncol Lett. 2021 Jul;22(1):512. doi: 10.3892/ol.2021.12773. Epub 2021 May 5.
7
Clinicopathological Profiles of and Patterns of Recurrence in Triple-Negative Breast Cancer Patients at a Cancer Care Center in Southern India.印度南部一家癌症护理中心三阴性乳腺癌患者的临床病理特征及复发模式
Cureus. 2024 Jul 5;16(7):e63886. doi: 10.7759/cureus.63886. eCollection 2024 Jul.
8
Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.三阴性乳腺癌分子亚型的细化：对新辅助化疗选择的影响
PLoS One. 2016 Jun 16;11(6):e0157368. doi: 10.1371/journal.pone.0157368. eCollection 2016.
9
Biology and Management of Patients With Triple-Negative Breast Cancer.三阴性乳腺癌患者的生物学特性与管理
Oncologist. 2016 Sep;21(9):1050-62. doi: 10.1634/theoncologist.2016-0067. Epub 2016 Jul 11.
10
Advancements and challenges in triple-negative breast cancer: a comprehensive review of therapeutic and diagnostic strategies.三阴性乳腺癌的进展与挑战：治疗与诊断策略的全面综述
Front Oncol. 2024 May 28;14:1405491. doi: 10.3389/fonc.2024.1405491. eCollection 2024.

引用本文的文献

1
Resolving tumor microenvironment heterogeneity to forecast immunotherapy response in triple-negative breast cancer through multi-scale analysis.通过多尺度分析解析肿瘤微环境异质性以预测三阴性乳腺癌的免疫治疗反应
Front Oncol. 2025 Aug 19;15:1538574. doi: 10.3389/fonc.2025.1538574. eCollection 2025.
2
Soy and Isoflavones: Revisiting Their Potential Links to Breast Cancer Risk.大豆与异黄酮：重新审视它们与乳腺癌风险的潜在联系
Nutrients. 2025 Aug 13;17(16):2621. doi: 10.3390/nu17162621.
3
Molecular Mechanisms of Radiation Resistance in Breast Cancer: A Systematic Review of Radiosensitization Strategies.

本文引用的文献

1
Biomarker role of thyroid irAE and PD-L1 positivity in predicting PD-1 blockade efficacy in patients with non-small cell lung cancer.甲状腺免疫相关不良事件和 PD-L1 阳性在预测非小细胞肺癌患者 PD-1 阻断疗效中的生物标志物作用。
Cancer Immunol Immunother. 2024 Oct 9;73(12):260. doi: 10.1007/s00262-024-03852-w.
2
Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into "ARness".局部晚期三阴性乳腺癌新辅助内分泌治疗和化疗的Ⅱ期临床研究：试验结果和对“AR 状态”的深入了解
Cell Rep Med. 2024 Jun 18;5(6):101595. doi: 10.1016/j.xcrm.2024.101595. Epub 2024 Jun 4.
3
乳腺癌放射抗性的分子机制：放射增敏策略的系统综述
Curr Issues Mol Biol. 2025 Jul 24;47(8):589. doi: 10.3390/cimb47080589.
4
Multiplex Immunofluorescence Reveals Therapeutic Targets EGFR, EpCAM, Tissue Factor, and TROP2 in Triple-Negative Breast Cancer.多重免疫荧光揭示三阴性乳腺癌中的治疗靶点表皮生长因子受体（EGFR）、上皮细胞黏附分子（EpCAM）、组织因子和人滋养层细胞表面抗原2（TROP2）
Int J Mol Sci. 2025 Aug 1;26(15):7430. doi: 10.3390/ijms26157430.
5
Estrogen receptor alpha dynamics and plasticity during endocrine resistance.内分泌抵抗期间雌激素受体α的动力学与可塑性
Biol Direct. 2025 Jun 13;20(1):70. doi: 10.1186/s13062-025-00653-8.
6
The R-RAS2 GTPase is a signaling hub in triple-negative breast cancer cell metabolism and metastatic behavior.R-RAS2 GTP酶是三阴性乳腺癌细胞代谢和转移行为中的一个信号枢纽。
J Hematol Oncol. 2025 Apr 12;18(1):41. doi: 10.1186/s13045-025-01693-3.
Cancer biomarkers: Emerging trends and clinical implications for personalized treatment.
癌症生物标志物：个性化治疗的新兴趋势和临床意义。
Cell. 2024 Mar 28;187(7):1617-1635. doi: 10.1016/j.cell.2024.02.041.
4
Exploration of drug resistance mechanisms in triple negative breast cancer cells using a microfluidic device and patient tissues.使用微流控装置和患者组织探索三阴性乳腺癌细胞的耐药机制。
Elife. 2024 Mar 27;12:RP88830. doi: 10.7554/eLife.88830.
5
Recent advances in targeted strategies for triple-negative breast cancer.三阴性乳腺癌靶向治疗策略的最新进展。
J Hematol Oncol. 2023 Aug 28;16(1):100. doi: 10.1186/s13045-023-01497-3.
6
Systemic Therapy for Metastatic Triple Negative Breast Cancer: Current Treatments and Future Directions.转移性三阴性乳腺癌的全身治疗：当前治疗方法与未来方向
Cancers (Basel). 2023 Jul 26;15(15):3801. doi: 10.3390/cancers15153801.
7
Is the Androgen Receptor a Viable Target in Triple Negative Breast Cancer in 5 Years?雄激素受体在 5 年内是否能成为三阴性乳腺癌的可行靶点？
Clin Breast Cancer. 2023 Dec;23(8):813-824. doi: 10.1016/j.clbc.2023.06.009. Epub 2023 Jun 20.
8
Targeting triple-negative breast cancer: A clinical perspective.靶向三阴性乳腺癌：临床视角。
Oncol Res. 2023 May 24;31(3):221-238. doi: 10.32604/or.2023.028525. eCollection 2023.
9
Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trial.基于亚型的平台指导了对经大量预处理的转移性三阴性乳腺癌的精准医学治疗：FUTURE 二期伞式临床试验。
Cell Res. 2023 May;33(5):389-402. doi: 10.1038/s41422-023-00795-2. Epub 2023 Mar 27.
10
Triple-Negative Breast Cancer and Predictive Markers of Response to Neoadjuvant Chemotherapy: A Systematic Review.三阴性乳腺癌与新辅助化疗反应的预测标志物：一项系统综述。
Int J Mol Sci. 2023 Feb 3;24(3):2969. doi: 10.3390/ijms24032969.